Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
Earnings Data
Report Date
Feb 03, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.82Last Year’s EPS
1.49Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook, with strong performance in key segments like Oncology and significant pipeline advancements. Challenges were noted in GARDASIL sales and certain product launches, but the strategic acquisition of Verona Pharma and robust pipeline developments indicate a strong future trajectory.Company Guidance
Solid Third Quarter Performance
Merck reported total company revenues of $17.3 billion, an increase of 4% or 3% excluding the impact of foreign exchange. Oncology and Animal Health segments showed significant growth.
KEYTRUDA Growth
Sales of KEYTRUDA increased 8% to $8.1 billion, driven by strong demand from metastatic indications and uptake in earlier-stage cancers.
Strategic Acquisition of Verona Pharma
Completion of the acquisition of Verona Pharma, adding a new growth driver with multibillion-dollar potential.
Strong Pipeline Advancements
Approximately 80 Phase III trials underway with significant progress in areas like cardiovascular, oncology, and immunology.
Positive Regulatory Milestones
FDA approval of KEYTRUDA QLEX for subcutaneous administration and positive CHMP opinion received.
DE:6MK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:6MK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | €74.80 | €74.20 | -0.80% |
Jul 30, 2025 | €69.23 | €71.41 | +3.15% |
Apr 24, 2025 | €67.95 | €67.56 | -0.58% |
Feb 04, 2025 | €93.42 | €83.31 | -10.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Merck & Company (DE:6MK) report earnings?
Merck & Company (DE:6MK) is schdueled to report earning on Feb 03, 2026, Before Open (Confirmed).
What is Merck & Company (DE:6MK) earnings time?
Merck & Company (DE:6MK) earnings time is at Feb 03, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Merck & Company stock?
The P/E ratio of Merck & Company is N/A.
What is DE:6MK EPS forecast?
DE:6MK EPS forecast for the fiscal quarter 2025 (Q4) is 1.82.
